Alzheimer Disease
18 competing products in clinical development for Alzheimer Disease.
Pipeline by Phase
Phase 13
Phase 29
Phase 2/32
Phase 34
All Products (18)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Donanemab + Placebo | Eli Lilly | Phase 3 | Recruiting | 77 |
| Simufilam + Placebo | Cassava Sciences | Phase 3 | Terminated | 69 |
| Simufilam + Placebo | Cassava Sciences | Phase 3 | Completed | 69 |
| Simufilam | Cassava Sciences | Phase 3 | Terminated | 69 |
| ATH-1017 | LeonaBio | Phase 2/3 | Terminated | 57 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | Completed | 57 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | Completed | 52 |
| donanemab | Eli Lilly | Phase 2 | Completed | 52 |
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | UNKNOWN | 44 |
| AL002 + Placebo | Alector | Phase 2 | Completed | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | Completed | 44 |
| Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet | Cassava Sciences | Phase 2 | Completed | 44 |
| Simufilam 100 mg oral tablet + Placebo | Cassava Sciences | Phase 2 | Completed | 44 |
| PTI-125, 100 mg tablets | Cassava Sciences | Phase 2 | Completed | 44 |
| IGC-AD1-Active + IGC-AD1-Placebo | IGC Pharma | Phase 2 | Recruiting | 44 |
| LY3002813-IV + LY3002813-SC + Placebo-IV | Eli Lilly | Phase 1 | Completed | 33 |
| LY3002813 + Placebo | Eli Lilly | Phase 1 | Completed | 33 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | Completed | 25 |